DENV-IN-10 is a potent tetravalent inhibitor of the dengue virus, with half-maximal effective concentrations (EC50s) of 1.36, 0.87, 0.94, and 0.95 μM against DENV-1, DENV-2, DENV-3, and DENV-4 serotypes, respectively. Functioning as a post-entry replication inhibitor, DENV-IN-10 demonstrates specificity for primate-origin cells [1].

DENV-IN-10 (10 µM; administered 2, 6, 12, 24 h before or after DENV infection) exhibited no significant antiviral activity when applied either before or immediately after infection. However, its addition 2 hours post-infection reduced infectious virus particle levels, and it remained effective even when administered 24 hours after infection [1]. DENV-IN-10 (10 µM; 24-60 h) decreased viral RNA copy numbers and the expression of DENV-2 viral proteins NS3 and NS5 in infected Huh-7 cells [1]. DENV-IN-10 in a concentration range of 0.1-20 µM significantly inhibited the replication of DENV-2 in primate cell lines, although it showed higher EC50 values in mosquito cells and young hamster kidney cells [1].